BOSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today announced that the Company will participate in the following investor events during the month of May.

Details are as follows:

The Citizens Life Sciences Conference
Location: New York, NY
Date: Thursday, May 8, 2025
Time: 1:30 PM ET
Webcast Link: https://wsw.com/webcast/jmp65/cmpx/1692592

H.C. Wainwright 3^rd Annual BioConnect Investor Conference at NASDAQ
Location: New York, NY
Date: Tuesday, May 20, 2025
Time: 11:30AM ET
Webcast Link: https://journey.ct.events/view/29729b86-5109-46dc-a93b-1cf3560aa9a1

Virtual/Replay availability: Presentations will be archived for 90 days on Compass’ Events page.

About Compass Therapeutics

Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass’s scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. The company pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. Compass plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The company was founded in 2014 and is headquartered in Boston, Massachusetts. For more information, visit the Compass Therapeutics website at https://www.compasstherapeutics.com.

Investor Contact
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media Contact
Anna Gifford, Chief of Staff
This email address is being protected from spambots. You need JavaScript enabled to view it.
617-500-8099